Zhifei Longcom awarded Truking Huatong the honors of "Excellent Technical Team" and "Excellent Supplier"
2021-11-12 15:01
On August 6, Li Wanjun, Chairman of Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., Deputy General Manager Jiang Pan, and Project Manager Wei Pingzhi visited Truking Huadong for inspection. They awarded the Truking Huadong Zhifei Longcom Industrial Park R&D Center project and the COVID-19 vaccine project execution team, granting Truking Huadong the honors of "Excellent Technical Team" and "Excellent Supplier." They also awarded Truking Huadong employees Jiang Haiyang and Cai Fuqiang the titles of "Excellent Project Manager" and "Excellent Construction Manager," respectively. Additionally, commemorative silver coins for "Zhifei Biotech 100 Million Doses" were presented to Truking Huadong Chairman Yang Wenlu and employees Jiang Haiyang and Cai Fuqiang.
Yang Wenlu, Chairman of Truking Huadong, led heads of R&D, production, and engineering departments to hold a symposium with Li Wanjun, Chairman of Zhifei Longcom, and his delegation. Li Wanjun fully affirmed Truking Huadong's capabilities in technology R&D, manufacturing, and engineering, highly praising Truking Huadong's high-quality, high-standard, and efficient project delivery contributions to the large-scale production of Zhifei Longcom's COVID-19 vaccine. He expressed full recognition and trust in Truking Huadong's project team, stating, "We expect Truking Huadong to continue leveraging team strength, overcoming difficulties, and promoting smooth project delivery in the upcoming COVID-19 vaccine bulk drug project. Zhifei Longcom and Truking Huadong will work together to make greater contributions to fighting the COVID-19 pandemic."
In 2020, Truking Huadong and Zhifei Longcom began significant cooperation on the Industrial Park R&D Center project. In 2021, they collaborated on key projects including the COVID-19 vaccine bulk drug water system, distribution system, and inactivation system. Truking Huadong attaches great importance to project production and delivery, with Chairman Yang Wenlu personally deploying and following up on key project milestones. The project team adheres to Truking's business philosophy of "customer-centric, based on strivers, and guided by goals, responsibilities, and results," advancing project production and delivery through close teamwork and strong execution, creating significant value for customers and earning high recognition.
Yang Wenlu, Chairman of Truking Huadong, accompanied by relevant department heads, led a thorough visit and inspection with Li Wanjun, Chairman of Zhifei Longcom, and his delegation, engaging in in-depth exchanges on Zhifei Longcom's COVID-19 vaccine-related projects. Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. It is a high-tech enterprise integrating bioproduct research, production, and sales, mainly engaged in the R&D and production of immunological agents, vaccines, gene recombinant products, and other bioproducts. It serves public health and is committed to realizing the grand vision of the "Biological Dream, Health Dream, China Dream, and Zhifei Dream."
In January 2020, Zhifei Longcom collaborated with the Institute of Microbiology, Chinese Academy of Sciences, to jointly develop a recombinant subunit COVID-19 vaccine. This project was included in the national emergency special key R&D program "Public Safety Risk Prevention and Emergency Technology Equipment" key special project. The team devoted full efforts to developing the recombinant protein vaccine for COVID-19, achieving significant research results. In June of the same year, it officially entered clinical trials, becoming China's first recombinant protein vaccine to reach the clinical stage. Zhifei Longcom raced against time on the path of COVID-19 vaccine R&D and production, demonstrating the speed and strength of China’s COVID-19 vaccine efforts and making important contributions to the global fight against the pandemic.